General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Rapid Micro Biosystems in Its Initial Public Offering

August 4, 2021
A Boston-based team advises the innovative life sciences technology company in the offering and underwriter exercise of its over-allotment option.

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (Rapid Micro), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, has announced that the underwriters of its previously announced US$158.4 million initial public offering of Class A common stock have exercised their option to purchase additional shares in part for 1,086,604 shares at the public offering price of US$20 per share less underwriting discounts and commissions, for additional gross proceeds to Rapid Micro of US$21.7 million.

Latham & Watkins LLP represents Rapid Micro Biosystems, Inc. in the offering with a Boston-based deal team led by partners Wesley Holmes and Stephen Ranere, with associates Jennifer Yoon, Tyler Mills, and Dante Spurlock.